Aleigha Lawless

619 total citations
21 papers, 218 citations indexed

About

Aleigha Lawless is a scholar working on Oncology, Molecular Biology and Immunology. According to data from OpenAlex, Aleigha Lawless has authored 21 papers receiving a total of 218 indexed citations (citations by other indexed papers that have themselves been cited), including 14 papers in Oncology, 8 papers in Molecular Biology and 6 papers in Immunology. Recurrent topics in Aleigha Lawless's work include Cancer Immunotherapy and Biomarkers (11 papers), Cutaneous Melanoma Detection and Management (6 papers) and Melanoma and MAPK Pathways (6 papers). Aleigha Lawless is often cited by papers focused on Cancer Immunotherapy and Biomarkers (11 papers), Cutaneous Melanoma Detection and Management (6 papers) and Melanoma and MAPK Pathways (6 papers). Aleigha Lawless collaborates with scholars based in United States, Australia and United Kingdom. Aleigha Lawless's co-authors include Ryan J. Sullivan, Matteo S. Carlino, Douglas B. Johnson, Georgina V. Long, Alexander M. Menzies, Suthee Rapisuwon, James R. Patrinely, Hui‐Ling Yeoh, Iman Osman and Andrew Haydon and has published in prestigious journals such as Journal of Clinical Oncology, Clinical Chemistry and Annals of Surgical Oncology.

In The Last Decade

Aleigha Lawless

17 papers receiving 216 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Aleigha Lawless United States	4	179	54	48	43	19	21	218
Elisabetta Gambale Italy	8	178 1.0×	116 2.1×	47 1.0×	40 0.9×	20 1.1×	19	246
Diego Enrico Argentina	8	136 0.8×	64 1.2×	42 0.9×	45 1.0×	7 0.4×	29	215
Shuping Ding China	5	106 0.6×	26 0.5×	57 1.2×	77 1.8×	9 0.5×	7	177
Ahmed Bilal Khalid United States	3	145 0.8×	103 1.9×	70 1.5×	54 1.3×	36 1.9×	7	241
Yu Yu China	5	139 0.8×	60 1.1×	32 0.7×	53 1.2×	12 0.6×	6	197
Patricia Rich United States	7	103 0.6×	39 0.7×	54 1.1×	27 0.6×	41 2.2×	19	159
Viola Ghizzoni Italy	9	112 0.6×	36 0.7×	75 1.6×	45 1.0×	27 1.4×	27	303
Luisa Piccin Italy	5	167 0.9×	69 1.3×	30 0.6×	53 1.2×	11 0.6×	16	219
Anne Sibille Belgium	9	137 0.8×	83 1.5×	53 1.1×	28 0.7×	29 1.5×	21	204
Ningning Li China	8	97 0.5×	55 1.0×	70 1.5×	35 0.8×	20 1.1×	27	240

Countries citing papers authored by Aleigha Lawless

Since Specialization

Citations

This map shows the geographic impact of Aleigha Lawless's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Aleigha Lawless with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Aleigha Lawless more than expected).

Fields of papers citing papers by Aleigha Lawless

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Aleigha Lawless. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Aleigha Lawless. The network helps show where Aleigha Lawless may publish in the future.

Co-authorship network of co-authors of Aleigha Lawless

This figure shows the co-authorship network connecting the top 25 collaborators of Aleigha Lawless. A scholar is included among the top collaborators of Aleigha Lawless based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Aleigha Lawless. Aleigha Lawless is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Wehrenberg-Klee, Eric, Antoine Desîlets, Marlana Orloff, et al.. (2025). Concurrent local therapy extends clinical benefit of tebentafusp in metastatic uveal melanoma patients. The Oncologist. 30(10).

Oliveira, Solange, Nayara Gusmão Tessarollo, Ana Paula Lepique, et al.. (2025). Use of patient-derived organotypic tumor spheroids for testing of viral vector gene therapy in combination with checkpoint blockade. PubMed. 33(1). 200942–200942. 1 indexed citations

Lawless, Aleigha, Tatyana Sharova, Alexander M. Menzies, et al.. (2025). Real‐World Outcomes of Adjuvant Therapy in Stage III Melanoma and the Impact of Somatic Mutations. Cancer Medicine. 14(23). e71410–e71410.

Goodman, Rachel, Aleigha Lawless, Rachel Woodford, et al.. (2025). Characterizing Chronic Cutaneous Immune-Related Adverse Events Following Immune Checkpoint Inhibitors. JAMA Dermatology. 161(5). 555–555. 1 indexed citations

Irlmeier, Rebecca, Xue Bai, Fei Ye, et al.. (2025). Impact of steroid dose and timing on efficacy of combination PD-1/CTLA-4 blockade. OncoImmunology. 14(1). 2494433–2494433. 1 indexed citations

Perdigoto, Ana Luisa, Jacqueline E. Mann, Martha Torres, et al.. (2025). Factors that increase class I MHC expression may contribute to the development of immune checkpoint inhibitor-induced diabetes. Journal for ImmunoTherapy of Cancer. 13(9). e012358–e012358.

Morak, Monika, Lucie Heinzerling, Aleigha Lawless, et al.. (2025). Retrospective multicenter analysis of real-life toxicity and outcome of ipilimumab and nivolumab in metastatic uveal melanoma. The Oncologist. 30(7). 1 indexed citations

Boutros, Andrea, Aleigha Lawless, Georgina V. Long, et al.. (2025). Characteristics and predictors of chronic immune-related adverse events (irAEs) following anti-PD-1 (PD1) treatment for melanoma.. Journal of Clinical Oncology. 43(16_suppl). 9528–9528. 1 indexed citations

Jan, Yu Jen, et al.. (2024). Body mass index and type 2 diabetes mellitus as metabolic determinants of immune checkpoint inhibitors response in melanoma. Journal for ImmunoTherapy of Cancer. 12(11). e009769–e009769. 1 indexed citations

10.

Sierra-Davidson, Kailan, Aikaterini Dedeilia, Aleigha Lawless, et al.. (2024). Genetic Factors Associated with Clinical Response in Melanoma Patients Treated with Talimogene Laherparapvec: A Single-Institution Retrospective Analysis. Annals of Surgical Oncology. 32(1). 482–494. 2 indexed citations

11.

Sierra-Davidson, Kailan, Aikaterini Dedeilia, Aleigha Lawless, et al.. (2024). ASO Visual Abstract: Genetic Factors Associated with Clinical Response in Melanoma Patients Treated with Talimogene Laherparepvec—A Single-Institution Retrospective Analysis. Annals of Surgical Oncology. 32(4). 2773–2774.

12.

Gragoudas, Evangelos S., Anne Marie Lane, Mary E. Aronow, et al.. (2024). Detection of Copy-Number Variation in Circulating Cell-Free DNA in Patients With Uveal Melanoma. JCO Precision Oncology. 8(8). e2300368–e2300368. 3 indexed citations

13.

Goodman, Rachel, Aleigha Lawless, Rachel Woodford, et al.. (2023). Extended Follow-Up of Chronic Immune-Related Adverse Events Following Adjuvant Anti–PD-1 Therapy for High-Risk Resected Melanoma. JAMA Network Open. 6(8). e2327145–e2327145. 30 indexed citations

14.

Goodman, Rachel, Aleigha Lawless, Rachel Woodford, et al.. (2023). Long-term outcomes of chronic immune-related adverse events from adjuvant anti-PD-1 therapy for high-risk resected melanoma.. Journal of Clinical Oncology. 41(16_suppl). 9591–9591. 3 indexed citations

15.

Kuijpers, Anke, Firas Kreidieh, Teresa Amaral, et al.. (2023). Efficacy of adjuvant therapy in patients (pts) with AJCC v8 stage IIIA cutaneous melanoma.. Journal of Clinical Oncology. 41(16_suppl). 9518–9518. 3 indexed citations

16.

Dedeilia, Aikaterini, Thinzar M. Lwin, Siming Li, et al.. (2023). Factors Affecting Recurrence and Survival for Patients with High-Risk Stage II Melanoma. Annals of Surgical Oncology. 31(4). 2713–2726. 8 indexed citations

17.

Blewett, Timothy, Justin Rhoades, Ruolin Liu, et al.. (2023). MAESTRO-Pool Enables Highly Parallel and Specific Mutation-Enrichment Sequencing for Minimal Residual Disease Detection in Cohort Studies. Clinical Chemistry. 70(2). 434–443. 4 indexed citations

18.

Patrinely, James R., Aleigha Lawless, Prachi Bhave, et al.. (2021). Chronic Immune-Related Adverse Events Following Adjuvant Anti–PD-1 Therapy for High-risk Resected Melanoma. JAMA Oncology. 7(5). 744–744. 152 indexed citations

19.

Mooradian, Meghan J., Florian J. Fintelmann, Howard Kaufman, et al.. (2021). The use of cryoablation to overcome resistance to PD-1 blockade in unresectable melanoma.. Journal of Clinical Oncology. 39(15_suppl). 9538–9538. 2 indexed citations

20.

Mooradian, Meghan J., Florian J. Fintelmann, Riley Fadden, et al.. (2019). A phase II study of cryoablation (cryo) of an enlarging tumor in patients (pts) with advanced lung cancer or melanoma receiving post-progression immune checkpoint inhibition (ICI).. Journal of Clinical Oncology. 37(15_suppl). e14243–e14243. 3 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact